Immuron (IMRN) Income towards Parent Company (2016 - 2024)
Immuron's quarterly Income towards Parent Company came in at -$1.6 million in Q4 2024, up 21.49% year-on-year from -$1.3 million in Q1 2024, and up 21.49% quarter-over-quarter from -$2.1 million in Q4 2023.
Immuron has reported Income towards Parent Company for 9 years, with the latest figure at -$1.6 million in Q4 2024.
- For the quarter ending Q4 2024, Income towards Parent Company rose 21.49% year-over-year to -$1.6 million; the trailing twelve-month figure through Sep 2025 stood at -$1.6 million (up 21.49% YoY), and the FY2025 full-year result was -$3.4 million, up 25.69% from the prior year.
- Income towards Parent Company for Q4 2024 stood at -$1.6 million, up from -$2.1 million in the prior quarter.
- The five-year high for Income towards Parent Company was $2.4 million in Q3 2023, with the low at -$2.1 million in Q4 2023.
- Average Income towards Parent Company over 5 years is -$108145.1, with a median of -$57387.7 recorded in 2020.
- Year-over-year, Income towards Parent Company plunged 277.25% in 2020 and soared 13946.4% in 2022.
- Tracing IMRN's Income towards Parent Company over 5 years: stood at -$57387.7 in 2020, then soared by 77.0% to -$13196.5 in 2021, then soared by 13946.4% to $1.8 million in 2022, then plunged by 213.46% to -$2.1 million in 2023, then climbed by 21.49% to -$1.6 million in 2024.
- The last three Income towards Parent Company figures came in at -$1.6 million (Q4 2024), -$2.1 million (Q4 2023), and $2.4 million (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 28, 2023 | 2.43 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -13,196.46 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.56 Mn |
| Jun 30, 2016 | -3.28 Mn |